Our team is proud to lead the way in research and development of devices to help treat heart valve disease. In fact, Penn doctors have been responsible for some of the most exciting and innovative new techniques for heart valve repair and replacement. View our current clinical trials and research:
The study is a multi-center, prospective, single-arm, and non-randomized study designed to evaluate the safety and function of the Edwards Lifesciences CardiAQ™ Transcatheter Mitral Valve with the Transfemoral and Transapical Delivery Systems.
Prospective, randomized, parallel-controlled, multicenter clinical evaluation of the MitraClip device for treatment of clinically significant functional mitral regurgitation in symptomatic heart failure subjects who are treated per standard of care and who have been determined by the site’s local heart team as not appropriate for mitral valve surgery.
PARTNER 3 – SAPIEN 3
Transcatheter Heart Valve in Low Risk Patients with Aortic Stenosis
Prospective, randomized, controlled, multi-center trial. Patients having an operative mortality < 2% (low operative risk) for surgical aortic valve replacement will be randomized 1:1 to receive either transcatheter heart valve replacement (TAVR) with the Edwards SAPIEN 3 or aortic valve replacement with a commercially available surgical bioprosthetic valve. Patients will be seen for follow-up visits at discharge, 30 days, 6 months, and annually through 10 years.
A prospective, multi-center, randomized, controlled clinical study, designed to evaluate the safety and effectiveness of the SJM Portico Transcatheter Heart Valve and Delivery Systems (Portico) via transfemoral and alternative delivery methods. Designed for High Risk / Extreme Risk patient cohort.
The objective of this study is to evaluate the safety and effectiveness of the Lotus™ Valve System for transcatheter aortic valve replacement (TAVR) in symptomatic subjects with calcific, severe native aortic stenosis who are considered at extremeor high risk for surgical valve replacement.
The purpose of the study is to investigate the safety and efficacy of transcatheter aortic valve implantation (TAVI) in patients with severe, symptomatic Aortic Stenosis (AS) at intermediate surgical risk by randomizing patients to either Surgical Aortic Valve Replacement (SAVR) or TAVI with the Medtronic CoreValve® System.